Neovascular (Wet) Age-related Macular Degeneration Clinical Trial
Official title:
A Prospective, Non-interventional, Multicenter, Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With Neovascular (Wet) Age-related Macular Degeneration (nAMD)
This is a Prospective, Non-interventional, Multicenter, Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients with Neovascular (Wet) Age-related Macular Degeneration (nAMD). All subject who completed the parent clinical study (NCT06213038 and NCT05986864) will undergo safety and efficacy assessments up to 5 years post study drug injection.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04126317 -
Safety, Tolerability, and Efficacy of Aflibercept in Patients With Neovascular Age-Related Macular Degeneration
|
Phase 2 | |
| Completed |
NCT06184360 -
Real-world Evaluation of BEOVU (Brolucizumab) Effectiveness and Durability for Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD)
|
||
| Completed |
NCT04847895 -
Observation of Treatment Patterns With Lucentis® in Real-life Conditions in All Approved Indications
|
||
| Active, not recruiting |
NCT05439629 -
Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Macular Degeneration
|
Phase 3 | |
| Recruiting |
NCT05197270 -
4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration
|
Phase 1/Phase 2 | |
| Terminated |
NCT05473715 -
A Study to Learn How Well Aflibercept Injected Into the Eye Works and How Safe it is When Given in Customized Treatment Intervals in Patients With an Eye Disease Called Neovascular Age-related Macular Degeneration After Start of Treatment
|
Phase 4 |